http://gistsupport.org GIST Support International is a support group of patients and families affected by gastrointestinal stromal tumor. GIST Support International is dedicated to education and support of GIST patients and families and friends. I just found out I have GIST. en Copyright 2010, GIST Support International admin@yourdomain.com admin@yourdomain.com GIST Support International Website Baker Content Management System Watch videos from Dana-Farber's April 2010 event.

]]> http://www.gistsupport.org/posts/living-with-gist-10-years-of-molecularly-targeted-therapy-180.php http://www.gistsupport.org/posts/living-with-gist-10-years-of-molecularly-targeted-therapy-180.php free access online

]]> http://www.gistsupport.org/posts/esmo-gist-guidelines-183.php http://www.gistsupport.org/posts/esmo-gist-guidelines-183.php Becky and Carolyn report for GIST Support International

]]> http://www.gistsupport.org/posts/asco-2010-news-on-gist-182.php http://www.gistsupport.org/posts/asco-2010-news-on-gist-182.php 2010 recommendations from experts

]]> http://www.gistsupport.org/posts/nccn-gist-task-force-update-181.php http://www.gistsupport.org/posts/nccn-gist-task-force-update-181.php state-of-the-art for GIST

]]> http://www.gistsupport.org/posts/esmo-gist-meeting-177.php http://www.gistsupport.org/posts/esmo-gist-meeting-177.php http://www.gistsupport.org/posts/sarcoma-awareness-week-171.php http://www.gistsupport.org/posts/sarcoma-awareness-week-171.php supporting trial for pediatric & wildtype GIST

]]> http://www.gistsupport.org/posts/578-signed-r1507-petition-170.php http://www.gistsupport.org/posts/578-signed-r1507-petition-170.php Access videos and webcasts from the meeting.

]]> http://www.gistsupport.org/posts/gist-at-2009-asco-163.php http://www.gistsupport.org/posts/gist-at-2009-asco-163.php ]]> http://www.gistsupport.org/posts/5-year-adjuvant-gleevec-trial-for-resected-high-risk-gist164.php http://www.gistsupport.org/posts/5-year-adjuvant-gleevec-trial-for-resected-high-risk-gist164.php Participate in GIST research!

]]> http://www.gistsupport.org/posts/project-flag136.php http://www.gistsupport.org/posts/project-flag136.php http://www.gistsupport.org/posts/sunitinib-approved-in-uk162.php http://www.gistsupport.org/posts/sunitinib-approved-in-uk162.php http://www.gistsupport.org/posts/gist-management-2009-update157.php http://www.gistsupport.org/posts/gist-management-2009-update157.php http://www.gistsupport.org/posts/attending-a-gist-cme-event158.php http://www.gistsupport.org/posts/attending-a-gist-cme-event158.php http://www.gistsupport.org/posts/adjuvant-imatinib-in-europe161.php http://www.gistsupport.org/posts/adjuvant-imatinib-in-europe161.php http://www.gistsupport.org/posts/igf-signals-in-gist134.php http://www.gistsupport.org/posts/igf-signals-in-gist134.php http://www.gistsupport.org/posts/sorafenib-is-promising117.php http://www.gistsupport.org/posts/sorafenib-is-promising117.php http://www.gistsupport.org/posts/sutent-conditionally-approved-in-eu52.php http://www.gistsupport.org/posts/sutent-conditionally-approved-in-eu52.php http://www.gistsupport.org/posts/fda-approves-adjuvant-imatinib155.php http://www.gistsupport.org/posts/fda-approves-adjuvant-imatinib155.php http://www.gistsupport.org/posts/ctos-and-sarc-meet-in-london149.php http://www.gistsupport.org/posts/ctos-and-sarc-meet-in-london149.php http://www.gistsupport.org/posts/nih-clinic-for-ped-wildtype-gist148.php http://www.gistsupport.org/posts/nih-clinic-for-ped-wildtype-gist148.php http://www.gistsupport.org/posts/duensings-new-gist-findings147.php http://www.gistsupport.org/posts/duensings-new-gist-findings147.php http://www.gistsupport.org/posts/nih-pediatric-gist-clinic125.php http://www.gistsupport.org/posts/nih-pediatric-gist-clinic125.php http://www.gistsupport.org/posts/adjuvant-gleevec-trial-news68.php http://www.gistsupport.org/posts/adjuvant-gleevec-trial-news68.php http://www.gistsupport.org/posts/z9000-adjuvant-imatinib-trial118.php http://www.gistsupport.org/posts/z9000-adjuvant-imatinib-trial118.php http://www.gistsupport.org/posts/esmo-gist-session138.php http://www.gistsupport.org/posts/esmo-gist-session138.php http://www.gistsupport.org/posts/nilotinib-trial-opens135.php http://www.gistsupport.org/posts/nilotinib-trial-opens135.php http://www.gistsupport.org/posts/new-italian-gist-group59.php http://www.gistsupport.org/posts/new-italian-gist-group59.php http://www.gistsupport.org/posts/treating-gist114.php http://www.gistsupport.org/posts/treating-gist114.php http://www.gistsupport.org/posts/plasma-imatinib-levels116.php http://www.gistsupport.org/posts/plasma-imatinib-levels116.php http://www.gistsupport.org/posts/sarcoma-video71.php http://www.gistsupport.org/posts/sarcoma-video71.php http://www.gistsupport.org/posts/attention-for-gi-cancers115.php http://www.gistsupport.org/posts/attention-for-gi-cancers115.php http://www.gistsupport.org/posts/nilotinib-compassionate-access-ends113.php http://www.gistsupport.org/posts/nilotinib-compassionate-access-ends113.php http://www.gistsupport.org/posts/sunitinib-heart-failure112.php http://www.gistsupport.org/posts/sunitinib-heart-failure112.php http://www.gistsupport.org/posts/2007-nccn-task-force-on-gist100.php http://www.gistsupport.org/posts/2007-nccn-task-force-on-gist100.php CancerWise ]]> http://www.gistsupport.org/posts/gist-featured-at-mda99.php http://www.gistsupport.org/posts/gist-featured-at-mda99.php World Congress on Gastrointestinal Cancer (Webcasts)

]]> http://www.gistsupport.org/posts/world-congress-on-gastrointestinal-cancer39.php http://www.gistsupport.org/posts/world-congress-on-gastrointestinal-cancer39.php http://www.gistsupport.org/posts/predicting-side-effects88.php http://www.gistsupport.org/posts/predicting-side-effects88.php http://www.gistsupport.org/posts/gsi-signs-bad-nauheim-declaration87.php http://www.gistsupport.org/posts/gsi-signs-bad-nauheim-declaration87.php http://www.gistsupport.org/posts/bike-tour-funds-awarded57.php http://www.gistsupport.org/posts/bike-tour-funds-awarded57.php http://www.gistsupport.org/posts/team-sarcoma-200769.php http://www.gistsupport.org/posts/team-sarcoma-200769.php http://www.gistsupport.org/posts/do-not-interrupt-gleevec72.php http://www.gistsupport.org/posts/do-not-interrupt-gleevec72.php http://www.gistsupport.org/posts/hsp90-inhibitor-progress67.php http://www.gistsupport.org/posts/hsp90-inhibitor-progress67.php http://www.gistsupport.org/posts/free-access-gist-reviews66.php http://www.gistsupport.org/posts/free-access-gist-reviews66.php http://www.gistsupport.org/posts/cancercare-gist-teleconference64.php http://www.gistsupport.org/posts/cancercare-gist-teleconference64.php http://www.gistsupport.org/posts/sutent-and-thyroid-function62.php http://www.gistsupport.org/posts/sutent-and-thyroid-function62.php http://www.gistsupport.org/posts/gist-summit-webcasts63.php http://www.gistsupport.org/posts/gist-summit-webcasts63.php http://www.gistsupport.org/posts/cardiotoxicity-from-imatinib53.php http://www.gistsupport.org/posts/cardiotoxicity-from-imatinib53.php http://www.gistsupport.org/posts/slide-presentation-from-dr.-peter-reichardt15.php http://www.gistsupport.org/posts/slide-presentation-from-dr.-peter-reichardt15.php http://www.gistsupport.org/posts/managing-sutent-side-effects61.php http://www.gistsupport.org/posts/managing-sutent-side-effects61.php http://www.gistsupport.org/posts/warning-gleevec-heart-effects58.php http://www.gistsupport.org/posts/warning-gleevec-heart-effects58.php ]]> http://www.gistsupport.org/posts/dr.-von-mehren-on-gist55.php http://www.gistsupport.org/posts/dr.-von-mehren-on-gist55.php http://www.gistsupport.org/posts/pet-scans-medicare54.php http://www.gistsupport.org/posts/pet-scans-medicare54.php http://www.gistsupport.org/posts/gsi-attends-asco51.php http://www.gistsupport.org/posts/gsi-attends-asco51.php http://www.gistsupport.org/posts/sutent-approved-in-canada50.php http://www.gistsupport.org/posts/sutent-approved-in-canada50.php

]]> http://www.gistsupport.org/posts/searchable-online-canadian-database-of-health-product-adverse-reactions20.php http://www.gistsupport.org/posts/searchable-online-canadian-database-of-health-product-adverse-reactions20.php http://www.gistsupport.org/posts/novartis-gist-registry45.php http://www.gistsupport.org/posts/novartis-gist-registry45.php http://www.gistsupport.org/posts/esmo-gistsarcoma-meeting49.php http://www.gistsupport.org/posts/esmo-gistsarcoma-meeting49.php http://www.gistsupport.org/posts/sarcoma-awareness-week48.php http://www.gistsupport.org/posts/sarcoma-awareness-week48.php http://www.gistsupport.org/posts/sunitinib-advances-in-europe46.php http://www.gistsupport.org/posts/sunitinib-advances-in-europe46.php http://www.gistsupport.org/posts/sutent-benefits-over-half-of-trial-patients9.php http://www.gistsupport.org/posts/sutent-benefits-over-half-of-trial-patients9.php This new drug is entering a Phase I trial at Dana Farber Cancer Center for patients with GIST who have progressed on Gleevec. Trial participants may have tried other drugs besides Gleevec.

]]> http://www.gistsupport.org/posts/phase-i-clinical-trial-of-ipi-5048.php http://www.gistsupport.org/posts/phase-i-clinical-trial-of-ipi-5048.php http://www.gistsupport.org/posts/4-year-follow-up-of-gleevec3.php http://www.gistsupport.org/posts/4-year-follow-up-of-gleevec3.php http://www.gistsupport.org/posts/sutent-approved-for-gist7.php http://www.gistsupport.org/posts/sutent-approved-for-gist7.php From the Oregon Health & Science University Cancer Institute, Department of Pathology, and Division of Hematology and Oncology, Oregon Health & Science University and Veterans Affairs Medical Center, Portland, OR; and Department of Pathology, Brigham & Women's Hospital, Boston, MA

]]> http://www.gistsupport.org/posts/biology-of-gastrointestinal-stromal-tumors--corless-et-al.-22-18-3813--journal-of-clinical-oncology37.php http://www.gistsupport.org/posts/biology-of-gastrointestinal-stromal-tumors--corless-et-al.-22-18-3813--journal-of-clinical-oncology37.php This EurekAlert neww story indicates a trial of AMN107 is coming soon for GIST. AMN107 is a followup to Gleevec being developed by Novartis.

]]> http://www.gistsupport.org/posts/study-finds-new-designer-drug-is-potent-treatment-for-chronic-myelogenous-leukemia26.php http://www.gistsupport.org/posts/study-finds-new-designer-drug-is-potent-treatment-for-chronic-myelogenous-leukemia26.php To Log In:
http://www.pharmalive.com/subscriptions/news.cfm?nid=185956&from=%2FNews%2F%3Farticleid%3D185956%26categoryid%3D21

]]> http://www.gistsupport.org/posts/pharmalive-chemgenex-to-initiate-phase-ii-study-with-quinamed-in-prostate-cancer-anti-cancer-activity-observed-in-recently-completed-phase-i-study36.php http://www.gistsupport.org/posts/pharmalive-chemgenex-to-initiate-phase-ii-study-with-quinamed-in-prostate-cancer-anti-cancer-activity-observed-in-recently-completed-phase-i-study36.php As part of an agency-wide initiative to speed development of new medical products through the science of pharmacogenomics, the Food and Drug Administration (FDA) today issued a final guidance titled "Pharmacogenomic Data Submissions."

]]> http://www.gistsupport.org/posts/fda-works-to-speed-the-advent-of-new-more-effective-personalized-medicines24.php http://www.gistsupport.org/posts/fda-works-to-speed-the-advent-of-new-more-effective-personalized-medicines24.php Below is an informal summary of a consensus summary on GIST treatment by an international group of GIST experts. The consensus conference to develop this guideline was sponsored by the European Society of Medical Oncology (ESMO) with a grant from Novartis. A meeting was held in March 2004 among 41 experts from 12 countries from around the world (not just Europe). The resulting paper was published in March 2005 in the Annals of Oncology, volume 16 pages 566-578. The paper is not free-access. This is a paper your oncologist should obtain and read. Its purpose is to continue in the path started by the NCCN guidelines (which it cites) to develop a standard of care for GIST.

]]> http://www.gistsupport.org/posts/consensus-meeting-for-the-management-of-gastrointestinal-stromal-tumors-report-of-the-gist-consensus-conference-of-32004-under-the-auspices-of-esmo22.php http://www.gistsupport.org/posts/consensus-meeting-for-the-management-of-gastrointestinal-stromal-tumors-report-of-the-gist-consensus-conference-of-32004-under-the-auspices-of-esmo22.php http://www.gistsupport.org/posts/molecular-testing-in-patients-with-rare-cancer-predicts-response-to-gleevec21.php http://www.gistsupport.org/posts/molecular-testing-in-patients-with-rare-cancer-predicts-response-to-gleevec21.php http://www.gistsupport.org/posts/su11248-effective-in-treatment-of-gist-after-imatinib-is-ineffective19.php http://www.gistsupport.org/posts/su11248-effective-in-treatment-of-gist-after-imatinib-is-ineffective19.php This Medscape interview is free-access, but Medscape requires a simple user registration to view its content.

]]> http://www.gistsupport.org/posts/the-implications-of-kinase-mutations-in-clinical-practice-an-interview-on-gist-with-dr.-michael-heinrich18.php http://www.gistsupport.org/posts/the-implications-of-kinase-mutations-in-clinical-practice-an-interview-on-gist-with-dr.-michael-heinrich18.php http://www.gistsupport.org/posts/personalized-medicine-moves-forward17.php http://www.gistsupport.org/posts/personalized-medicine-moves-forward17.php CIW ENA 2004: "16th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'. "

]]> http://www.gistsupport.org/posts/ciw-ena-200438.php http://www.gistsupport.org/posts/ciw-ena-200438.php Abstract of presentation by P Reichardt, D Pink, T Lindner, MC Heinrich, P Cohen, Y Wang, A Tsyrlova, A Yap, S Dimitirijevic, CD Blanke
at the 2004 European Society for Medical Oncology congress

]]> http://www.gistsupport.org/posts/a-phase-iii-trial-of-the-oral-pkc-inhibitor-pkc412-pkc-and-imatinib-mesylate-im-in-patients-pts-with-gastrointestinal-stromal-tumor-gist35.php http://www.gistsupport.org/posts/a-phase-iii-trial-of-the-oral-pkc-inhibitor-pkc412-pkc-and-imatinib-mesylate-im-in-patients-pts-with-gastrointestinal-stromal-tumor-gist35.php Abstract of presentation by SN Finketstein, DM Huse, GA Glendenning, CD Blanke, H Joensuu, M von Mehren, GD Demetri at the 2004 European Society for Medical Oncology congress.

]]> http://www.gistsupport.org/posts/imatinib-cost-effective-in-the-treatment-of-gastrointestinal-stromal-tumors34.php http://www.gistsupport.org/posts/imatinib-cost-effective-in-the-treatment-of-gastrointestinal-stromal-tumors34.php Abstract of presentation by G Demetri, M von Mehren, H Joensuu, S Finketstein, D Huse, B Kiese, K McDougal, S Dimitrijevic, GA Glendenning, C Blanke at the 2004 European Society for Medical Oncology congress.

]]> http://www.gistsupport.org/posts/lack-of-progression-is-the-most-clinically-significant-measure-of-a-patients-clinical-benefit...33.php http://www.gistsupport.org/posts/lack-of-progression-is-the-most-clinically-significant-measure-of-a-patients-clinical-benefit...33.php VIENNA, AUSTRIA -- November 4, 2004 -- Lack of progression is the most clinically significant predictor of a patient's response to imatinib in patients with gastrointestinal stromal tumours (GIST), a new analysis shows.

]]> http://www.gistsupport.org/posts/esmo-tumor-shrinkage-doesnt-predict-response-to-imatinib-therapy-in-patients-with-gastrointestinal-stromal-tumors32.php http://www.gistsupport.org/posts/esmo-tumor-shrinkage-doesnt-predict-response-to-imatinib-therapy-in-patients-with-gastrointestinal-stromal-tumors32.php Not only can positron emission tomography (PET) help evaluate treatment for gastrointestinal stromal tumors (GIST) by revealing biologic changes such as how the tumor processes the fuel that makes it grow, but CT can indirectly reveal biologic changes as well by analyzing the tumor's density, say researchers from The University of Texas M. D. Anderson Cancer Center in Houston.

]]> http://www.gistsupport.org/posts/tumor-size-alone-not-always-best-for-gauging-treatment-response31.php http://www.gistsupport.org/posts/tumor-size-alone-not-always-best-for-gauging-treatment-response31.php Swedish researchers developed a method of predicting the probability GIST will recur after surgery.

]]> http://www.gistsupport.org/posts/new-point-system-enhances-prognosis-for-gist-patients28.php http://www.gistsupport.org/posts/new-point-system-enhances-prognosis-for-gist-patients28.php BROKEN!!!

]]> http://www.gistsupport.org/posts/chemgenex-presents-positive-clinical-trial-data-on-anticancer-compound-quinamed-at-u.s.-cancer-conference27.php http://www.gistsupport.org/posts/chemgenex-presents-positive-clinical-trial-data-on-anticancer-compound-quinamed-at-u.s.-cancer-conference27.php BROKEN!!!

]]> http://www.gistsupport.org/posts/forbes.com-update-2-drug-firms-create-promote-discount-card25.php http://www.gistsupport.org/posts/forbes.com-update-2-drug-firms-create-promote-discount-card25.php   ]]> http://www.gistsupport.org/posts/gastrointestinal-stromal-tumours-a-report-by-b.-landuyt-at-van-oosterom16.php http://www.gistsupport.org/posts/gastrointestinal-stromal-tumours-a-report-by-b.-landuyt-at-van-oosterom16.php http://www.gistsupport.org/posts/patientinform13.php http://www.gistsupport.org/posts/patientinform13.php http://www.gistsupport.org/posts/pfizer-submits-application-to-fda-for-sutent-su1124812.php http://www.gistsupport.org/posts/pfizer-submits-application-to-fda-for-sutent-su1124812.php http://www.gistsupport.org/posts/amn107-trial-for-gist-patients11.php http://www.gistsupport.org/posts/amn107-trial-for-gist-patients11.php http://www.gistsupport.org/posts/ecco-13--sunitinib-prolongs-survival-in-gist-patients-after-imatinib-mesylate-failure10.php http://www.gistsupport.org/posts/ecco-13--sunitinib-prolongs-survival-in-gist-patients-after-imatinib-mesylate-failure10.php